中文 | English

Case sharing: Application of artificial intelligence in drug discovery

Event details

DATE
Wednesday Nov 24th, 2021

VENUE
Online Webex / Zoom

TIME
10:00 – 11:00 Berlin time (CET)
16:00 - 17:00 Beijing time (GMT+8)

RSVP
This is a complimentary event
VIP tickets priority for Lingmed current clients
Please RSVP by Nov 23rd, 2021
PRESENTERS
Lingling Cao, CEO & Founder
Dr Han Wen, R&D Scientist, DeepSense Technology
Dr Glenn Gilbert, Guest speaker

REGISTER
+86 21 5386 3003
BD@lingmed.net

Agenda

CET 10:00 - 10:30 – Case sharing: Artificial intelligence technology is applied in drug discovery’s multiple stages
– Limitations of the AI technology in drug discovery
by Dr Han Wen  (Chinese)
CET 10:30 - 10:35Linkedbio services & projects introductions    by Lingling Cao  (English)
CET 10:35 - 10:55Guest speaker:research spotlight on an Australian biotech company innovation breakthrough by Dr Glenn Gilbert   (English)
CET 10:55 – 11:00Q&A (English & Chinese)

Presenters

Dr Han Wen
R&D Director, Beijing DP Technology
Dr. Wen received his PhD in Physics from the State University of New York at Buffalo, USA, followed by a postdoctoral fellowship at the CCBR, University of Toronto. He has extensive research experience in molecular dynamics simulation, membrane proteins and deep learning-driven macromolecular drug design, with results published in top journals such as PNAS and JMC. He is currently a full-time scienentist at Beijing DP Technology, responsible for ion channel realated research and macromolecular drug design.

Dr Glenn Gilbert
Rhythm Biosciences Ltd
A pragmatic and commercial driven leader with over 17 years of experience in the healthcare sector (incl. pharmaceutical, medical device (Rx and OTC) and IVD industry) across domestic and international markets. His expertise spans strategy, manufacturing and sales, with a sharp focus on disciplined execution through culture, relationships and planning. Glenn has held leadership roles at Seqirus, a CSL company (ASX:CSL), and recently at Medical Developments International (ASX:MVP) with extensive business experience across the UK, Europe, Asia, North and South America. He specialises in mergers and acquisitions, corporate development, operations, intellectual property and legal portfolios

Lingling Cao
CEO & Founder
Lingling has more than a decade of experience in the healthcare industry, especially in deal-making. She founded Lingmed, which aims to support BD professionals to make better decisions with intelligence databases and EU-China cross-border deals. Prior to her venture at Lingmed, she was a senior BD manager for Eli Lilly in Shanghai and a consultant for McKinsey in Germany

Download meeting reports
©Copyright 2013 - 2021 Lingmed Limited